These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 31397223)
1. Nutrient and genetic biomarkers of nutraceutical treatment response in mood and psychotic disorders: a systematic review. van der Burg KP; Cribb L; Firth J; Karmacoska D; Sarris J Nutr Neurosci; 2021 Apr; 24(4):279-295. PubMed ID: 31397223 [No Abstract] [Full Text] [Related]
2. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. Sarris J; Ravindran A; Yatham LN; Marx W; Rucklidge JJ; McIntyre RS; Akhondzadeh S; Benedetti F; Caneo C; Cramer H; Cribb L; de Manincor M; Dean O; Deslandes AC; Freeman MP; Gangadhar B; Harvey BH; Kasper S; Lake J; Lopresti A; Lu L; Metri NJ; Mischoulon D; Ng CH; Nishi D; Rahimi R; Seedat S; Sinclair J; Su KP; Zhang ZJ; Berk M World J Biol Psychiatry; 2022 Jul; 23(6):424-455. PubMed ID: 35311615 [TBL] [Abstract][Full Text] [Related]
3. EPA and DHA as markers of nutraceutical treatment response in major depressive disorder. van der Burg KP; Cribb L; Firth J; Karmacoska D; Mischoulon D; Byrne GJ; Bousman C; Stough C; Murphy J; Oliver G; Berk M; Ng CH; Sarris J Eur J Nutr; 2020 Sep; 59(6):2439-2447. PubMed ID: 31555976 [TBL] [Abstract][Full Text] [Related]
4. Clinical use of nutraceuticals in the adjunctive treatment of depression in mood disorders. Sarris J Australas Psychiatry; 2017 Aug; 25(4):369-372. PubMed ID: 28135835 [TBL] [Abstract][Full Text] [Related]
5. The role of n-3 polyunsaturated fatty acids (n-3PUFAs) in affective disorders. Ciappolino V; Delvecchio G; Agostoni C; Mazzocchi A; Altamura AC; Brambilla P J Affect Disord; 2017 Dec; 224():32-47. PubMed ID: 28089169 [TBL] [Abstract][Full Text] [Related]
6. Effects of Omega 3 Fatty Acids on Main Dimensions of Psychopathology. Bozzatello P; De Rosa ML; Rocca P; Bellino S Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839416 [TBL] [Abstract][Full Text] [Related]
7. Omega-3 fatty acids in psychiatry: a review. Freeman MP Ann Clin Psychiatry; 2000 Sep; 12(3):159-65. PubMed ID: 10984006 [TBL] [Abstract][Full Text] [Related]
8. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. Freeman MP; Hibbeln JR; Wisner KL; Davis JM; Mischoulon D; Peet M; Keck PE; Marangell LB; Richardson AJ; Lake J; Stoll AL J Clin Psychiatry; 2006 Dec; 67(12):1954-67. PubMed ID: 17194275 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of omega-3 fatty acids in mood disorders - a systematic review and metaanalysis. Kraguljac NV; Montori VM; Pavuluri M; Chai HS; Wilson BS; Unal SS Psychopharmacol Bull; 2009; 42(3):39-54. PubMed ID: 19752840 [TBL] [Abstract][Full Text] [Related]
10. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. Lin PY; Su KP J Clin Psychiatry; 2007 Jul; 68(7):1056-61. PubMed ID: 17685742 [TBL] [Abstract][Full Text] [Related]
11. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone. Robinson DG; Gallego JA; John M; Hanna LA; Zhang JP; Birnbaum ML; Greenberg J; Naraine M; Peters BD; McNamara RK; Malhotra AK; Szeszko PR Schizophr Res; 2019 Feb; 204():295-303. PubMed ID: 30241990 [TBL] [Abstract][Full Text] [Related]
13. [The role of omega-3 fatty acids in the treatment of bipolar disorders: the current situation]. Sempels C; Sienaert P Tijdschr Psychiatr; 2007; 49(9):639-47. PubMed ID: 17853373 [TBL] [Abstract][Full Text] [Related]
14. Association of plasma ω-3 and ω-6 lipids with burden of disease measures in bipolar subjects. Evans SJ; Kamali M; Prossin AR; Harrington GJ; Ellingrod VL; McInnis MG; Burant CF J Psychiatr Res; 2012 Nov; 46(11):1435-41. PubMed ID: 22884424 [TBL] [Abstract][Full Text] [Related]
16. [Membrane lipids in schizophrenia and early phases of psychosis: Potential biomarkers and therapeutic targets?]. Frajerman A; Kebir O; Chaumette B; Tessier C; Lamazière A; Nuss P; Krebs MO Encephale; 2020 Jun; 46(3):209-216. PubMed ID: 32151446 [TBL] [Abstract][Full Text] [Related]
17. Omega-3 polyunsaturated fatty acid blood biomarkers increase linearly in men and women after tightly controlled intakes of 0.25, 0.5, and 1 g/d of EPA + DHA. Patterson AC; Chalil A; Aristizabal Henao JJ; Streit IT; Stark KD Nutr Res; 2015 Dec; 35(12):1040-51. PubMed ID: 26500082 [TBL] [Abstract][Full Text] [Related]
18. The role of omega-3 fatty acids in mood disorders. Stahl LA; Begg DP; Weisinger RS; Sinclair AJ Curr Opin Investig Drugs; 2008 Jan; 9(1):57-64. PubMed ID: 18183532 [TBL] [Abstract][Full Text] [Related]
19. Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder? Föcking M; Dicker P; Lopez LM; Cannon M; Schäfer MR; McGorry PD; Smesny S; Cotter DR; Amminger GP BMC Psychiatry; 2016 Sep; 16(1):326. PubMed ID: 27650124 [TBL] [Abstract][Full Text] [Related]
20. DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder. Goud Alladi C; Etain B; Bellivier F; Marie-Claire C Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30287754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]